SGLT2 inhibitors (empagliflozin, dapagliflozin) have demonstrated significant cardiovascular mortality reduction in heart failure patients even without diabetes. What is the proposed primary mechanism for their cardiac benefit?

• A SGLT2 inhibitors inhibit cardiac NHE1 (Na+/H+ exchanger), reducing intracellular Na+ and Ca2+ overload in cardiomyocytes and improving diastolic function, combined with diuretic and erythropoietic effects ✓
• B SGLT2 inhibitors reduce cardiac preload and afterload through sodium and glucose diuresis, leading to plasma volume reduction and improved hemodynamics
• C Direct cardiac SGLT1 inhibition reduces myocardial sodium and calcium overload via Na+/H+ exchanger inhibition, while systemic effects include reduced oxidative stress and improved mitochondrial function
• D The cardiac benefit is entirely mediated by weight loss and reduced insulin resistance improving myocardial metabolism

Explanation

The cardiovascular benefits of SGLT2 inhibitors are multifactorial and extend beyond glycemic control. Proposed mechanisms include: (1) Inhibition of the cardiac NHE1 (Na+/H+ exchanger), reducing intracellular Na+ and secondarily Ca2+ via NCX, improving diastolic function and reducing arrhythmia risk — this direct cardioprotective effect is independent of SGLT2 renal effects; (2) Osmotic/natriuretic diuresis reducing preload; (3) Erythropoietic effect (increased erythropoietin, improved O2 delivery); (4) Induction of ketogenesis providing ketone bodies as an efficient cardiac fuel ('thrifty substrate hypothesis'); (5) Reduction of fibrosis, inflammation, and RAAS activation. The NHE1 inhibition is increasingly cited as the central direct cardiac mechanism.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.